Cerevel Therapeutics Holdings Inc (DELISTED) (CERE:DL)
44.96
0.00 (0.00%)
USD |
NASDAQ |
Aug 01, 16:00
Cerevel Therapeutics Holdings Enterprise Value: 7.683B for Aug. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 01, 2024 | 7.683B |
| July 31, 2024 | 7.683B |
| July 30, 2024 | 7.623B |
| July 29, 2024 | 7.583B |
| July 26, 2024 | 7.621B |
| July 25, 2024 | 7.581B |
| July 24, 2024 | 7.393B |
| July 23, 2024 | 7.399B |
| July 22, 2024 | 7.406B |
| July 19, 2024 | 7.308B |
| July 18, 2024 | 7.271B |
| July 17, 2024 | 7.275B |
| July 16, 2024 | 7.226B |
| July 15, 2024 | 7.126B |
| July 12, 2024 | 6.836B |
| July 11, 2024 | 6.971B |
| July 10, 2024 | 6.949B |
| July 09, 2024 | 6.876B |
| July 08, 2024 | 6.887B |
| July 05, 2024 | 6.954B |
| July 03, 2024 | 6.834B |
| July 02, 2024 | 7.004B |
| July 01, 2024 | 7.025B |
| June 28, 2024 | 6.942B |
| June 27, 2024 | 6.871B |
| Date | Value |
|---|---|
| June 26, 2024 | 6.590B |
| June 25, 2024 | 6.699B |
| June 24, 2024 | 7.038B |
| June 21, 2024 | 7.080B |
| June 20, 2024 | 7.086B |
| June 18, 2024 | 7.116B |
| June 17, 2024 | 7.047B |
| June 14, 2024 | 7.059B |
| June 13, 2024 | 7.069B |
| June 12, 2024 | 6.971B |
| June 11, 2024 | 6.830B |
| June 10, 2024 | 6.829B |
| June 07, 2024 | 6.783B |
| June 06, 2024 | 6.827B |
| June 05, 2024 | 6.945B |
| June 04, 2024 | 6.898B |
| June 03, 2024 | 6.894B |
| May 31, 2024 | 6.914B |
| May 30, 2024 | 6.896B |
| May 29, 2024 | 6.929B |
| May 28, 2024 | 6.962B |
| May 24, 2024 | 7.022B |
| May 23, 2024 | 7.076B |
| May 22, 2024 | 7.080B |
| May 21, 2024 | 7.102B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.191B
Minimum
Mar 30 2021
7.683B
Maximum
Jul 31 2024
4.044B
Average
3.881B
Median
Feb 15 2022
Enterprise Value Benchmarks
| AbbVie Inc | 364.87B |
| Amgen Inc | 213.42B |
| Biogen Inc | 28.75B |
| Gilead Sciences Inc | 110.38B |
| Eli Lilly and Co | 798.35B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -131.91M |
| Total Expenses (Quarterly) | 142.66M |
| EPS Diluted (Quarterly) | -0.73 |
| Earnings Yield | -6.07% |